Hennigsdorf, 15. November 2021 - The medical technology company Pentracor GmbH from Hennigsdorf has won the "Zukunftspreis Brandenburg" 2021, the most important business prize in the state. The high-caliber, 16-member jury praised in particular the company's medical innovative strength, regional networking with clinics and science, and attention from international research. The award ceremony took place on November 12 at the Airport Center Berlin Schönefeld in the presence of Minister President Dr. Dietmar Woidke.

Dr. Ahmed Sheriff, Managing Director of Pentracor GmbH, is honored: "We have already made great progress this year. The fact that our product has now been recognized as a groundbreaking innovation in medical technology and that we have been awarded the Zukunftspreis Brandenburg is particularly pleasing to us and shows that we are also gaining increasing recognition outside the medical community. This is a further incentive for us to consistently continue our determined expansion."

Der Grundstein für die Expansion wurde durch die 2020 erfolgte, erfolgreiche Anleihe-Emission gelegt, bei der Pentracor frisches Kapital zur weiteren Finanzierung aufnahm. Die fünfjährige Unternehmensanleihe (ISIN: DE000A289XB9, WKN: A289XB) mit einem jährlichen Zinssatz von 8,50 % und möglichem Wandlungsrecht ist seit dem 29. Mai 2020 im Open Market der Frankfurter Wertpapierbörse notiert und mit einer Stückelung von 1.000 EUR handelbar.

Worldwide unique therapy from Hennigsdorf

Pentracor's technology saves lives of Corona-infected patients in intensive care units. In addition, the blood washing process significantly reduces the loss of tissue after heart attacks or strokes, thus preserving the performance capacity of the people affected. Pentracor's so-called CRP apheresis can be an efficient therapeutic aid in other inflammatory diseases of the intestine (ulcerative colitis and Crohn's disease), the pancreas and rheumatoid diseases.

"I almost can't imagine intensive care medicine without CRP apheresis anymore," says Fabrizio Esposito, MD, the senior physician in charge of intensive care and emergency medicine as well as a cardiologist at Havelhöhe Hospital in Berlin. He has successfully treated numerous patients with Pentracor's blood washing procedure. "Currently, 16 clinics from the Allgäu region in the south to Flensburg in the north, including university hospitals, are using the blood washing procedure with continuously growing success. The trend for further clinic partners is increasing, as are sales," explains Dr. Sheriff. The Austrian university hospitals of Innsbruck, Salzburg and Graz are currently working on a large-scale study with CRP apheresis after myocardial infarction.

Innovation based on new basic research

Pentracor is the only company in the world that can specifically reduce the amount of CRP in the body. The background to Pentracor's groundbreaking therapy is a novel insight into the role of the protein CRP, supported by various studies. According to this understanding, this protein molecule, in an extension of the medical textbook opinion, not only serves as a measure of the severity of an inflammation and for marking inflamed tissue and subsequent removal by the scavenger cells of the no longer viable inflamed cells. Rather, CRP also functions as a trigger amplifying the inflammatory events of various diseases. CRP is then frequently involved in the cell death of still viable as well as healthy cells in the case of ischemia (reduced blood flow -> oxygen depletion). The problem is always characterized by a strongly increased synthesis of CRP.

At this year's "Zukunftspreis Brandenburg" 2021, six prize winners and one company as a special prize winner were chosen from 82 applicants and 12 finalists. The partners of the most important business award in Brandenburg include the six chambers of commerce - IHKs and HwKs - as well as renowned institutions such as Wirtschaftsförderung Land Brandenburg GmbH. In addition, companies, banks, employment agencies in the state of Brandenburg and several media partners are among the circle of supporters.

A short film produced by Märkisches Medienhaus on the occasion of the award ceremony as well as further impressions are available at: https://www.pentracor.de/news/pentracor-mit-zukunftspreis-brandenburg-2021-ausgezeichnet/.

About the Pentracor GmbH

Die Pentracor GmbH, Medizintechnikunternehmen in Brandenburg, entwickelt, erforscht wie produziert und vermarktet mit PentraSorb® CRP den einzigen selektiv wirksamen Adsorber zur Entfernung eines entzündungsfördernden Eiweißkörpers aus dem Blutplasma. Immunadsorption bei Inflammation wird damit zur wirksamen Therapie überschießender Entzündungsreaktionen in den verschiedensten Krankheitsbildern. Mit einem erwarteten Potential von mehr als 200 Millionen Euro allein zur Behandlung von akuten Herzinfarkten gehört die selektive CRP-Apherese zu den vielversprechendsten Innovationen in der Medizintechnik. Im November 2021 wurde die Gesellschaft mit dem wichtigsten Wirtschaftspreis des Landes Brandenburg, dem „Zukunftspreis Brandenburg“ 2021, ausgezeichnet.

Company contact

Pentracor GmbH
CEO Ahmed Sheriff
+49 3302 20 94 49-0

Financial and economic press

IR.on AG

+49 221 9140 970